In 2015, Phase I clinical trial (NCT 02397005) was initiated to evaluate tolerability and pharmacokinetics of the selective and reversible hPGDS inhibitor ZL-2102 for treatment of COPD, asthma and idiopathic pulmonary fibrosis [135]. Here, HPGDS is linked to chronic obstructive pulmonary disease.